Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vidofludimus in Inflammatory Bowel Disease (ENTRANCE)
NCT00820365Phase 2Completed
- Sponsor
- 4SC AG
- Start
- Mar 2009
- Primary completion
- Oct 2010
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of vidofludimus calcium in Crohn's disease and ulcerative colitis (UC), sponsored by 4SC AG. Primary endpoint: Efficacy (Complete or Partial Response) at 12 weeks. Started Mar 2009; status: completed.
02
Drugs
vidofludimus calcium
03
Conditions
Crohn's diseaseulcerative colitis (UC)
Beyond the preview
Go deeper on NCT00820365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00820365.